Geneva, 21 May 2021 – Gavi, the Vaccine Alliance announced today that it has signed an advance purchase agreement with Johnson & Johnson for its single-dose vaccine against COVID-19. The agreement is for a commitment to purchase 200 million doses on behalf of the COVAX Facility, with the goal of them being supplied to Facility participants in 2021.
Supply of the vaccine will be available to both self-financing and Gavi COVAX AMC-eligible participants. Gavi will continue to assess the COVAX Facility portfolio and participants’ needs and will remain in discussions with Johnson & Johnson on potential supply of 300 million additional doses in 2022.
“Today’s agreement between Gavi and Johnson & Johnson means the COVAX Facility is able to offer participants yet another safe and effective tool against the pandemic. I welcome Johnson & Johnson’s commitment to equitable access and to expanding global manufacturing through external partnerships, which is something that will provide long-lasting benefits even after this pandemic is over,” said Dr Seth Berkley, CEO of Gavi. “As a one-dose vaccine, the J&J vaccine has particular relevance for places with difficult infrastructure, making it a very important addition to the portfolio.”
The COVAX Facility portfolio, administered by Gavi, currently consists of agreements related to 8 vaccines and vaccine candidates – AstraZeneca/Oxford, Pfizer, Moderna, Novavax, Johnson & Johnson, SII-Covishield, SII-Covovax, and Sanofi/GSK – with the aim to expand to 10-12 vaccines in total, providing participants access to a diverse range of vaccines suitable for use in varied contexts and settings.
“Since the earliest days of the pandemic, we have been steadfast in our goal to facilitate equitable access to our COVID-19 vaccine,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “No one is safe from COVID-19 until everyone is protected, and our partnership with Gavi is the single greatest step we have taken to ensure our single-shot vaccine is accessible to everyone, everywhere. Our commitment today offers the potential to protect up to 500 million people from COVID-19.”
In order to continue diversifying and expanding the portfolio, and secure access to early supply in the future, Gavi is seeking to raise at least an additional US$1.6 billion for the COVAX AMC. This will allow Gavi, on behalf of the COVAX AMC, to lock in as many as 1.8 billion doses of vaccine for its 92 lower-income economies. As part of this effort, the Government of Japan will be hosting the upcoming Gavi COVAX AMC Summit, bringing together world leaders, the private sector, civil society and key technical partners in a virtual event on June 2nd.
In addition to doses secured via agreements with manufacturers, Gavi and its COVAX partners the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization and UNICEF also call on the international community to share doses with COVAX immediately to help those countries that have been worst hit by current global supply constraints and urgently need to protect their most at-risk populations.